MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) has placed 490,133 shares in a private placement at a price of € 35.50 per share. The company raised gross proceeds of approx. € 17.4 million. WestLB AG acted as Sole Lead Manager of the transaction.
The issue proceeds will be used to capitalize on existing and future expansion opportunities to accelerate internal and external sales growth primarily in MorphoSys' activities in the field of research antibodies.
With the capital increase, the number of issued shares will increase from 5,438,852 to 5,928,985 shares, corresponding to an increase of subscribed share capital in common stock from €16,316,556 to €17,786,955.
To ensure a timely delivery of shares to new investors, WestLB AG has entered into share loan agreements with Schering AG, Dr. Simon E. Moroney, Chief Executive Officer of MorphoSys AG, and Prof. Andreas Plückthun, member of the Supervisory Board of MorphoSys AG.
'Although MorphoSys was profitable last year, the capital increase helps to increase the financial flexibility of the company in regards to future growth' commented Dave Lemus, Chief Financial Officer at MorphoSys AG.